OrthoPediatrics opened higher at $33.75, compared with its previous close of $33.67. In the last trading session, the stock traded between $32.30 and $34.48. It showed a downward intraday trend.
An investment of $100 made 5 years ago in OrthoPediatrics is now worth
$ 48.88
Resulting in a loss of
$ 51.12 (51.12%)
Note: Past profits do not guarantee future returns.
Rating from 7 Analysts
Today's Change
$-1.05 (-3.12%)
Day High
$34.48
Day Low
$32.30
Day Open
$33.75
Prev Close
$33.67
Volume
1,28,524
1W Return
-2.94%
1M Return
47.36%
3M Return
34.53%
6M Return
89.86%
1Y Return
89.53%
Market Cap ($ Mn)
852
PE Ratio
-
PB Ratio
1.80
PEG Ratio
-
ROE
-11.31%
ROCE
-7.34%
EPS (TTM)
$-0.23
1 Week
-2.94%
1 Month
47.36%
3 Months
34.53%
6 Months
89.86%
9 Months
89.42%
OrthoPediatrics launches VerteGlide system for scoliosis treatment
OrthoPediatrics Corp. launched the VerteGlide Spinal Growth Guidance System for Early Onset Scoliosis (EOS). The system provides three-dimensional deformity correction while preserving potential for continued spinal growth. VerteGlide utilizes Shilla technology licensed from Medtronic to address complex spinal deformities in children. Strong adoption across the U.S. reflects growing interest among pediatric spine surgeons in growth-guidance technologies.
3 days agoOrthoPediatrics to report Q3 2026 financial results on October 27
OrthoPediatrics releases Q3 2026 results on October 27, 2026. Conference call scheduled for 4:30 pm ET same day. Company markets over 95 systems in pediatric orthopedics. Products distributed in US and 75+ international markets.
1mo agoOrthoPediatrics launches 3P Hip System after 350+ implantations
OrthoPediatrics fully launches 3P Hip System in US after limited trial. Limited launch saw over 350 successful surgical implantations. System includes plates and screws for infant, child, and adolescent patients. First product in broader Pediatric Plating Platform portfolio. Company expects further systems to expand plating options globally.
2mo agoOrthoPediatrics to report Q2 2026 financial results on August 4
OrthoPediatrics Corp. will announce its Q2 2026 financial results on August 4, 2026, followed by a conference call at 4:30 p.m. ET. The company specializes in pediatric orthopedics, offering over 90 systems across trauma, deformity, scoliosis, and sports medicine. Investors can access the webcast replay on the company's website for 90 days.
3mo agoTruist Securities raises OrthoPediatrics price target to $20
Truist Securities analyst Richard Newitter maintains a Hold rating on OrthoPediatrics (NASDAQ: KIDS) and raises the price target to $20 from $17.
3mo agoOrthoPediatrics inks exclusive U.S. deal with OSSIO for pediatric fixation tech
OrthoPediatrics Corp. announced an exclusive distribution agreement with OSSIO, Inc. to provide bio-integrative, metal-free fixation technology to U.S. children’s hospitals. The OSSIOfiber implants, made from natural mineral fibers, integrate into bone tissue within 18–24 months, eliminating the need for secondary hardware removal surgeries. This partnership expands OrthoPediatrics' product portfolio and addresses unmet needs in pediatric orthopedics.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in OrthoPediatrics is now worth
$ 48.88
Resulting in a loss of
$ 51.12 (51.12%)
Note: Past profits do not guarantee future returns.
